SANOFI-ADR (SNY)

RSI Alert: Sanofi (SNY) Now Oversold

This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip?

Let's look beyond this piece of bad news from regulators.

FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals

US FLUBLOK label1 updated to incorporate new safety study in pregnant individuals New safety data involving more than 48,000 pregnant individuals published in...

Sanofi commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to increase diversity in clinical studies

/PRNewswire/ -- Sanofi announced today it will contribute $18 million to three Historically Black Medical Schools to help the institutions work to increase...

2 Artificial Intelligence Stocks That Could Deliver Explosive Gains

These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead.

NASDAQ:SNY is probably undervalued for the fundamentals it is displaying.

SANOFI-ADR (NASDAQ:SNY) is an undervalued gem with solid fundamentals.

Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent

The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD.

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Global Cancer Rates Surge as Biotech Innovators Work on New Therapies

/CNW/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase...

Global Cancer Rates Surge as Biotech Innovators Work on New Therapies

/PRNewswire/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84%...

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old

Sanofi shipping BEYFORTUS® in US to help protect babies against RSV disease; new manufacturing line approved by FDA

/PRNewswire/ -- Sanofi is shipping BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection doses in the US to private healthcare providers and to the Centers for...

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Should You Buy Novavax Stock After This Regulatory Win?

The biotech continues to earn important wins, but is it enough?